The strong association of EBV with NPC, coupled with the fact that a significant proportion of tumors express the LMP1 oncoprotein, has led to the development of numerous approaches to target LMP1 as a potential therapeutic for EBV-driven malignancies (Table 1). Here, PDLIM7 is linked to nasopharyngeal carcinoma.